MIRA PHARMACEUTICALS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
FL
Business Address
1200 BRICKELL AVENUE, MIAMI, FL, 33131
Mailing Address
324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA, FL, 33606
Phone
813-369-5150
EIN
853354547
Financial Overview
FY2025
$11.09M
Total Assets
$-0.51
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| 5 Annual insider ownership changes | February 17, 2026 | View on SEC |
| 8-K Current report of material events | February 2, 2026 | View on SEC |
| 8-K Current report of material events | December 22, 2025 | View on SEC |
| 8-K Current report of material events | December 5, 2025 | View on SEC |
| 424B5 Prospectus supplement | December 5, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Lead candidate Ketamir-2 is an oral ketamine analog for nerve pain with Phase 2a trials planned for early 2026.
- DEA confirmation that Ketamir-2 and MIRA-55 are not controlled substances simplifies clinical and distribution pathways.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.